摘要
目的:探讨吉西他滨联合顺铂治疗晚期胆系肿瘤的疗效及相关不良反应。方法:2008年1月-2012年12月本科收治的经病理确诊为晚期胆道系统恶性肿瘤26例,给予吉西他滨1000 mg/m2,静脉滴注,第1、8天;顺铂75 mg/m2,静脉滴注,第1天,每21天为一周期。结果:吉西他滨联合顺铂治疗晚期胆系肿瘤的客观有效率为34.6%(9/26),疾病控制率为73.1%(19/26),其中CR 1例,PR 8例,SD 10例,PD 7例;化疗后主要不良反应为恶心呕吐(21例,80.8%)、白细胞减少(18例,69.2%)、血小板减少(12例,46.2%)、血红蛋白减少(10例,38.5%)、肝功能损害(11例,42.3%)、口腔黏膜炎(8例,30.8%)、肾功能损害(5例,19.2%)、腹泻(5例,19.2%),均在可耐受范围。结论:吉西他滨联合顺铂治疗晚期胆道系统肿瘤有效,不良反应较轻,安全性良好。
Objective:To investigate the efficacy and safety of combination therapy of gemcitabine and cisplatin for advanced biliary tract cancer.Method:A total of 26 cases of advanced biliary tract cancer in our hospital from January 2008 to December 2012 accepted combination therapy of gemcitabine(1000 mg/m^2,intravenous infusion 30 min,qd,d1、8) and cisplatin(75 mg/m^2, intravenous infusion,qd,d1) every 21-day cycle. Result:The objective response rate of combination therapy of gemcitabine and cisplatin was 34.6%(9/26), disease control rate was 73.1%(19/26), including CR 1 case, PR 8 cases, SD 10 cases, PD 7 cases. The major adverse reactions were nausea and vomiting(80.8%),leukopenia(69.2%),thrombocytopenia(46.2%),hemoglobin decreased(38.5%), hepatic dysfunction(42.3%),oral mucositis(30.8%),renal dysfunction(19.2%),diarrhea(19.2%). Conclusion:The combination thrapy regime with gemcitabine and cisplatin is recommended for patients with advanced biliary tract cancer,which is effective and safe.
出处
《中国医学创新》
CAS
2014年第32期106-109,共4页
Medical Innovation of China
关键词
吉西他滨
顺铂
胆系肿瘤
化疗
Gemcitabine
Cisplatin
Biliary tract cancer
Chemotherapy